Results 141 to 150 of about 29,664 (291)

A Phase 2 Trial of Hydroxychloroquine in Individuals at Risk for Rheumatoid Arthritis

Arthritis &Rheumatology, EarlyView.
Objective Individuals with serum elevations of anti–cyclic citrullinated peptide (anti‐CCP) antibodies are at increased risk for future rheumatoid arthritis (RA). No pharmacologic interventions have been approved for the prevention of RA in such at‐risk individuals.
Kevin D. Deane, Christopher C. Striebich, Marie L. Feser, James R. O'Dell, Judith A. James, Jeffrey A. Sparks, John M. Davis III, Jonathan Graf, Maureen A. McMahon, Elizabeth B. Solow, Lindsy J. Forbess, Athan Tiliakos, Elena Schiopu, Maria I. Danila, Diane L. Horowitz, Jonathan Kay, Colin D. Strickland, Joel M. Guthridge, Cristina Arriens, Jennifer M. Grossman, M. Kristen Demoruelle, Elizabeth A. Bemis, Ashley Frazer‐Abel, Chelsie L. Fleischer, David A. Fox, Ted R. Mikuls, Melissa Greenleaf, Kate York, Sarah Walker, Lynette Keyes‐Elstein, Margie Byron, Janel Fedler, Ellen A. Goldmuntz, V. Michael Holers   +33 more
wiley   +1 more source

Impact of Early Antimalarial Adherence on Future Acute Care Utilization and Cost Among Patients With Rheumatoid Arthritis and Systemic Lupus Erythematosus: A Population‐Based Study

Arthritis &Rheumatology, EarlyView.
Objective To assess the association between early antimalarial adherence and future acute care utilization and cost in a population‐based cohort of incident rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Methods All patients with incident RA/SLE and new antimalarial use in British Columbia, Canada, between January 1997 and March 2022
Md Rashedul Hoque, Diane Lacaille, J. Antonio Aviña‐Zubieta, Mary A. De Vera, Yi Qian, Lawrence McCandless, John M. Esdaile, Hui Xie   +7 more
wiley   +1 more source

Simulating competition in the US bioeconomy to produce hard‐to‐electrify transportation fuels using limited biomass resources

Biofuels, Bioproducts and Biorefining, EarlyView.
Abstract This study presents a novel bioeconomy optimization framework, BiOpt, designed to address critical questions regarding the strategic use of limited US biomass resources for biofuel production. By integrating detailed techno‐economic analyses, life cycle assessments, and resource assessment data, BiOpt optimizes resource distributions across ...
Nicholas A. Carlson, Emily K. Newes, Kristen Lu, Eric C. D. Tan   +3 more
wiley   +1 more source

Trends in 25 years of antihypertensive agent utilization in Croatia – an alert for scientific community and healthcare providers

British Journal of Clinical Pharmacology, EarlyView.
Aims Hypertension is a leading modifiable risk factor for cardiovascular mortality worldwide. This study aimed to evaluate 25‐year trends in antihypertensive agent (AHA) utilization in Croatia between 2000 and 2024. Methods We conducted a national, population‐based analysis using IMS and IQVIA pharmaceutical databases.
Andrej Belančić, Marta Kučan Štiglić, Ana Jelaković, Bojan Jelaković, Dinko Vitezić   +4 more
wiley   +1 more source

Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria

British Journal of Clinical Pharmacology, EarlyView.
Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova, Yoana Lilova, Alexander Oscar, Alina Levi, Maria Kamusheva, Guenka Petrova   +5 more
wiley   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Zuranolone: A case study in (regulatory) rush to judgement?

British Journal of Clinical Pharmacology, EarlyView.
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove, Milutin Kostic, Barbara Mintzes, Gianna D'Ambrozio, Allen Shaughnessy   +4 more
wiley   +1 more source

Can boarding schools help looked after and vulnerable children improve academic attainment?

British Educational Research Journal, EarlyView.
Abstract The education of children in statutory care, or at the edge of care, is a serious concern for governments and policymakers. How to promote educational opportunities for these children can involve challenging and often contentious proposals. In this paper, we study one proposal put into practice in England: the provision to children who are in ...
David Murphy, Gianni De Fraja, Mike Adkins   +2 more
wiley   +1 more source

Robots, ledgers, and RevPAR: a blockchain-enabled AI-robotics conceptual model for sustainable hotel revenue and asset management. [PDF]

Front Robot AI
Jackson LA.
europepmc   +1 more source

Transforming Brain Health With Neurotechnology Convergence (Part II): Intelligent Neurointervention Systems for Neurological Disorders

Brain Health, EarlyView.
ABSTRACT Neurological disorders represent a critical domain within global health, necessitating advanced interventions to address complex pathologies such as tumors, functional disorders, and cerebrovascular diseases. Despite the proven benefits of early intervention, current treatment paradigms face significant challenges: (1) limited precision in ...
Qing Ye, Fei Peng, Chao Pan, Ping Zhang, Xuewei Xie, Zixiao Li, Yingxin Tang, Danyang Chen, Yuanwei Li, Jiawen Wu, Zao Han, Qing Dai, Quansheng Gu, Jizong Zhao, Zhouping Tang   +14 more
wiley   +1 more source